image credit: Pexels

Rentschler Biopharma to build cell and gene therapy manufacturing capabilities in the UK

As part of the agreement, Rentschler will invest in the site over the next five years to bolster their manufacturing capabilities.

This investment is expected to make a ‘major contribution’ to creating suitable manufacturing capability for cell and gene therapies, the CGT Catapult said in a statement.

The German company will establish manufacturing capability in advanced therapy medicinal products (ATMPs), including adeno-associated virus (AAV) Vectors for clinical trial supply.

Read More on Pharma Times